GLP1R and type 2 diabetes mellitus: Some of the newly emerging treatments used for T2DM, such as glucagon-like peptide-1 (GLP-1) receptor agonists and the sodium-glucose cotransporter-2 inhibitors, have, for example, showed promising outcomes in recent years in terms of providing additional cardiorenal benefits in addition to controlling diabetes [6].